The Diabetes Economy: Miraculins Scouts for Worldwide Markets

The Life Sciences Report: What is Miraculins Inc.’s (MOM:TSX.V) focus? Christopher Moreau: Our business plan is to focus on the in-licensing or acquisition of diagnostic and risk assessment technologies for diseases where there’s . . . → Read More: The Diabetes Economy: Miraculins Scouts for Worldwide Markets Similar Articles: Market Update (NYSE:LLY): FDA approves Boehringer-Lilly drug for type-2 diabetes patients Market Update (NYSE:LLY): New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies Company Update (NYSE:LLY): Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C